Skip to main content
Clinical Trials/NL-OMON37397
NL-OMON37397
Completed
Not Applicable

A pharmacokinetic study to compare the bioavailability between MK-0663 (etoricoxib ) 120 mg Tablets from Two Different Manufacturing Sites (Frosst Iberica, Spain versus Elkton, VA, USA). - MK-0663 (CS0177)

Merck Sharp & Dohme (MSD)0 sites24 target enrollmentStarted: TBDLast updated:

Overview

Phase
Not Applicable
Status
Completed
Sponsor
Merck Sharp & Dohme (MSD)
Enrollment
24

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • Male and female, between 18\-55 years of age, BMI 18\-30\.

Exclusion Criteria

  • Clinical significant abnormalities at medical research

Investigators

Sponsor
Merck Sharp & Dohme (MSD)

Similar Trials